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Abstract
Background: The standard three-dose schedule of hepatitis B vaccines is frequently not completed, especially in
adolescents. A primary study has confirmed the equivalence of a two-dose schedule of an Adult formulation of
hepatitis B vaccine [Group HBV_2D] to a three-dose schedule of a Paediatric formulation in adolescents (11-15
years) [Group HBV_3D]. This follow-up study evaluated the five year persistence of antibody response and immune
memory against the hepatitis B surface (anti-HBs) antigens five years after completion of primary vaccination.
Methods: A total of 234 subjects returned at the Year 5 time point, of which 144 subjects received a challenge
dose of hepatitis B vaccine. Blood samples were collected yearly and pre- and post-challenge dose to assess anti-
HBs antibody concentrations.
Results: At the end of five years, 79.5% (95% confidence interval [CI]: 71.7 - 86.1) and 91.4% (95% CI: 82.3 - 96.8) of
subjects who received the two-dose and three-dose schedules, respectively had anti-HBs antibody concentrations
≥10 mIU/mL. Post-challenge dose, all subjects had anti-HBs antibody concentration ≥10 mIU/mL and >94%
subjects had anti-HBs antibody concentration ≥100 mIU/mL. All subjects mounted a rapid anamnestic response to
the challenge dose. Overall, the challenge dose was well-tolerated.
Conclusion: The two-dose schedule of hepatitis B vaccine confers long-term immunogenicity and shows evidence
of immune memory for at least five years following vaccination.
Trial registration: Clinical Trials NCT00343915, NCT00524576
Background
Hepatitis B viral infections continue to be a serious glo-
bal health problem and are a cause of concern for public
health authorities [1]. The virus is estimated to have
infected two billion people around the world, of whom
approximately 360 million are chronically infected.
These chronically infected individuals are at increased
risk of developing serious illness, which may progress to
liver cirrhosis and hepatocellular carcinoma (HCC), that
account for an estimated annual 500,000-700,000 deaths
worldwide [1]. A number of studies conducted in
different countries have confirmed that universal immu-
nisation of infants and/or adolescents is the most effi-
cient method of reducing the disease burden of hepatitis
B infection [2-5]. Taking into consideration the morbid-
ity and mortality associated with viral hepatitis world-
wide, the World Health Organization (WHO)
recommended in 1992 that vaccination against hepatitis
B should be included into the national immunisation
schedules of all countries worldwide by 1997 [1].
The three-dose schedule of hepatitis B vaccination has
been the standard immunisation schedule of choice. In
countries with an adolescent hepatitis B immunisation
programme, the completion rates, however, for the
three-dose schedule appear to be lower than expected in
certain target populations, such as adolescents [6,7]. In
addition, when compared to the option of a two-dose
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on the healthcare system in terms of the implementa-
tion and organisation of vaccination programmes.
Hence, there has been a growing interest among public
healthcare authorities and vaccine manufacturers in
identifying a suitable two-dose immunisation schedule
that is more convenient for use in adolescents to ensure
higher completion rates [7-9].
A two-dose schedule (0, 6 months) of a hepatitis B
vaccine (Engerix-B™: Adult formulation, GlaxoSmithK-
line [GSK] Biologicals, Belgium) has been approved for
use in European adolescents and is also one of the
recommended schedules for vaccination of adolescents
aged 11-15 years in Australia [10], United States and
Canada. In addition, a three-dose schedule of the Pae-
diatric formulation of this vaccine is recommended for
use in children and young adults aged <20 years. A pre-
vious study in children and adolescents has demon-
strated equivalence between a two-dose primary
vaccination schedule of the Adult formulation and a
three-dose schedule of the Paediatric formulation of this
vaccine in terms of seroprotection against hepatitis B
infection [8,11,12]. Considering that the risk of acquiring
hepatitis B infections is higher during early adulthood
due to various lifestyle-related exposure [13], it is critical
to assess the long-term persistence of vaccine-induced
immunity in young adults who have been vaccinated
with hepatitis B vaccine in their childhood.
The present study is a long-term follow-up to a pri-
mary study that has confirmed the non-inferiority of a
two-dose schedule of the Adult formulation of this
hepatitis B vaccine versus a three-dose schedule of the
Paediatric formulation, when comparing the anti-HBs
seroprotection rates and anti-HBs antibody GMCs at
Month 7 [4]. This follow-up study evaluated the five
year persistence of antibodies against hepatitis B surface
(anti-HBs) antigens in adolescents who received the
two-dose regimen of this hepatitis vaccine compared to
those who received the three-dose regimen, and the
ability of these subjects to mount an anamnestic
response to a challenge dose of hepatitis B vaccine given
five years after completion of primary immunisation.
Methods
Study design and subjects
In 2001, healthy adolescents aged between 11 and 15
years were enrolled into a single-blind, randomised,
multi-country study conducted in Belgium, Australia
and Ukraine. The subjects (randomisation blocking
scheme 2:1) received either two doses of Engerix-B™
Adult formulation (20 μg of recombinant hepatitis B
surface antigen [HBsAg], thiomersal-free formulation)
following a 0, 6 months schedule [Group HBV_2D] or
three doses of Engerix-B™ Paediatric formulation (10 μg
of recombinant HBsAg, preservative-free formulation)
following a 0, 1, 6 months schedule [Group HBV_3D].
Group HBV_2D additionally received an injection of
physiological saline as placebo at second vaccination
time point (Month 1) to maintain the blinding. The vac-
cines were administered as deep intramuscular injec-
tions (needle-length: 25 mm; gauge: 23) in the deltoid
region of the arm [4].
These subjects were then followed up for the next five
years (until Year 5 time point) with pre-defined annual
visits to evaluate the persistence of anti-HBs antibodies
induced by the two schedules of the hepatitis B vaccine
[NCT00343915]. Subjects who had completed the pri-
mary vaccination course of hepatitis B vaccines and met
the eligibility criteria for the challenge phase were admi-
nistered a challenge dose of hepatitis B vaccine (10 μg
of recombinant HBsAg, preservative-free formulation)
72-78 months later, were evaluated one month later for
immune memory to the HBs antigen [NCT00524576].
Subjects were excluded from the challenge phase if they
had used any investigational product within 30 days pre-
ceding the hepatitis B challenge dose or received/
planned to receive any vaccines unforeseen by the pro-
tocol within 30 days preceding or post-hepatitis B chal-
lenge dose or received an additional dose of hepatitis B
vaccine between the primary and challenge phases; sub-
jects were also excluded if they had confirmed of sus-
pected diagnosis of immunosuppressive or
immunodeficient condition. Pregnant or lactating female
subjects were also excluded.
The study was conducted respecting the Good Clinical
Practice (GCP) guidelines and Declaration of Helsinki.
Two of the four centres were eliminated from the eva-
luation of anamnestic response to the challenge dose;
the investigator from the study centre was not confident
that their team would be able to recruit a sufficient
number of subjects and therefore did not participate in
this phase of the study; while the subjects at another
s t u d yc e n t r ew e r ee x c l u d e df rom the primary analysis
due to GCP non-compliance.
The study protocol was approved by the independent
ethics committees of the Children’s Hospital at West-
mead, Antwerp University Hospital, UZA Wilrijkstraat,
HopitaloFacultaire de I’UCL and State Entreprise Centre
of Immunobiological Preparation; written informed con-
sent was obtained from the parents/guardians of adoles-
cent subjects and from subjects who were above 18
years of age before conducting any study-related
procedure.
Serological assessment
Anti-HBs antibody concentrations were measured in the
serum samples collected at the first two follow-up visits
(at Years 2 and 3 time points) using a commercial
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mIU/mL). For the subsequent visits (at Years 4 and 5
time points) and the challenge visits, an in-house quan-
titative enzyme-linked immunosorbent assay (cut-off:
≥3.3 mIU/mL) was used; this assay was equivalent to
the previously available commercial assay and was fully
validated by calibrating against the first International
Reference Preparation for anti-hepatitis B immunoglo-
bulin [14]. All evaluations were done at the Central
laboratory, GSK Biologicals, Belgium, except for the last
visit (at Year 5 and challenge visits), for which the eva-
luations were conducted at the CEVAC laboratory,
Ghent University and Hospital, Ghent, Belgium.
The percentage of subjects with anti-HBs antibody
concentrations ≥10 mIU/mL, GMCs, GMC evolution at
all follow-up time points was tabulated with 95% CI.
Assessment of safety
S a f e t ya s s e s s m e n to ft h ec h a l l e n g ed o s ei n c l u d e dp r o -
spective reporting of solicited local and general adverse
events and serious adverse events (SAEs). The adverse
events were graded on a three-point scale, with those
adverse events that hampered normal daily activities
being graded as Grade 3 symptoms.
Statistical analyses
No separate sample size calculations were conducted for
the long-term follow-up phase of the study. All subjects
who participated in the primary study were invited to
participate in the subsequent long-term follow-up time
points, subject to them meeting the inclusion and exclu-
sion criteria.
The primary analyses of immunogenicity at the long-
term follow-up time points (all four centres) were
performed on the long-term ATP cohort for immuno-
genicity, while for the challenge phase, the analyses were
performed on the ATP cohort for immunogenicity.
Assessments of safety for the challenge phase were per-
formed on the total vaccinated cohort (TVC).
The long-term ATP cohort for analyses of immuno-
genicity included those subjects who were part of the
ATP cohort for immunogenicity analyses in the primary
study, with available results from the long-term follow-
up time points and without any protocol violations. The
ATP immunogenicity cohort for the challenge phase
included those subjects who were protocol-compliant
and for whom post-challenge dose data was available.
An anamnestic response to the challenge dose was
defined taking into consideration the pre-challenge dose
serostatus of subjects; for seropositive subjects, an ana-
mnestic response was defined as a four-fold increase in
anti-HBs antibody concentration, and for seronegative
subjects, as an anti-HBs antibody concentrations ≥10
mIU/mL post-challenge.
GMCs were calculated by taking the anti-log of the
mean of log-transformed anti-HBs antibody concentra-
tion values.
All statistical analyses were performed using Statistical
Analysis System (SAS) version 9.1 and StatXact-7 on
SAS.
Results
Study population
The five years follow-up period concluded in January
2008 and a total of 234 subjects were available for this
follow-up visit. The challenge phase which concluded in
May 2008 included a total of 144 subjects. The number
of subjects who participated at each time point during
the long-term follow-up and the challenge phase is pre-
sented along with the reasons for non-participation of
other subjects in Figure 1.
The demographic characteristics in both groups were
similar at the time of recruitment for the primary vacci-
nation phase, at the Year 5 time point as well as at the
time of the challenge dose. In addition, there was no dif-
ference in demographic characteristics across the centres
in the three countries, at study start. Five years after the
primary immunisation, the overall mean age was 18.5 ±
1.44 years (range: 16-21 years) and 51.7% of subjects
were females; all subjects except two (99.1%) were of
Caucasian origin. At the time of the challenge dose,
mean age was 19.5 ± 1.30 years (range: 17-22 years);
50.7% of subjects were females and all subjects except
three (97.9%) were of Caucasian origin. The exclusion of
study centres in the challenge phase did not have any
impact on the demographic profile of the population, as
compared to the primary phase where 50.3% of subjects
were females and all except 11 subjects (97.1%) were of
Caucasian origin.
Immunogenicity
Antibody persistence
For the long-term follow-up period, the primary ana-
lyses of immunogenicity (long-term ATP cohort for
immunogenicity) were conducted on subjects from all
c e n t r e s ,w h i l ef o rt h ec h a l l e n g ep h a s e ,t h ep r i m a r ya n a -
lyses of immunogenicity and safety were performed on
subjects from two out of the four centres (ATP cohort
for immunogenicity).
Five years after the primary immunisation, 79.5% (95%
confidence interval [CI]: 71.7 - 86.1) of subjects in the
HBV_2D group and 91.4% (95% CI: 82.3 - 96.8) of sub-
jects in the HBV_3D group had anti-HBs antibody con-
centrations ≥10 mIU/mL (overlapping 95% confidence
intervals) (Figure 2). The anti-HBs antibody GMCs (cal-
culated on seropositive subjects) at all follow-up time
points appeared to be higher in subjects in the HBV_3D
group compared to those in the HBV_2D group (non-
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decrease of antibody concentrations was similar in both
groups, as shown by the parallel slopes of the GMC
kinetic curve (Figure 3A).
Immune memory
One month after the challenge dose, all subjects (100%)
in both groups had anti-HBs antibody concentrations
≥10 mIU/mL and a similar proportion of subjects in
both groups had anti-HBs antibody concentration ≥100
mIU/mL (HBV_2D: 94.3% [95% CI: 84.3 - 98.8];
HBV_3D: 95.2% [95% CI: 76.2 - 99.9]).
All subjects (100%) in both groups mounted an ana-
m n e s t i cr e s p o n s et ot h ec h a l l e n g ed o s eo fh e p a t i t i sB
vaccine irrespective of their pre-challenge dose serosta-
tus. All subjects who had diminishing levels of anti-HBs
antibodies before the challenge dose (<3.3 mIU/mL or
3.3-10 mIU/mL [pooled: seven and six subjects, respec-
tively]) showed anti-HBs antibody concentrations ≥10
mIU/mL after the challenge dose. In comparison, sub-
jects who had robust pre-challenge anti-HBs antibodies
concentrations (≥10 mIU/mL and ≥100 mIU/mL
[pooled: 35 and 26 subjects, respectively]) continued to
have similarly high anti-HBs antibody levels post-chal-
l e n g ed o s e( T a b l e1 ) .I nb o t hg r o u p s ,t h e r ew a sal a r g e
increase in the GMCs one month post-challenge dose
(HBV_2D: 6214.1 mIU/mL [108-fold increase, approxi-
mately]; HBV_3D: 16564.3 mIU/mL [95-fold increase,
approximately]) (Figure 3B).
Number of subjects enrolled (N=384) 
Group HBV_2D (N=258) Group HBV_3D (N=126)
Returned for blood sampling 
(N=179) 
LT-ATP analysis for 
immunogenicity (N=140) 
Returned for blood sampling 
(N=88)  
LT-ATP analysis for 
immunogenicity (N=64) 
Returned for blood sampling 
(N=84)  
LT-ATP analysis for 
immunogenicity (N=80) 
Returned for blood sampling 
(N=158)  
LT-ATP analysis for 
immunogenicity (N=132) 
Returned for blood sampling 
(N=76)  
LT-ATP analysis for 
immunogenicity at M66 
(N=70) 
Challenge phase: 144 subjects returned at the Australian and Belgian site, of which 74 subjects from the Belgian site were 
included in the ATP immunogenicity cohort [Exclusions: Non-evaluable participants: 67; non-compliance with blood sampling 
schedule: 2; Other: 1] 
Returned for blood sampling 
(N=174)  
LT-ATP analysis for 
immunogenicity (N=166) 
M30 (N=24) 
x Subjects who returned at M30 but 
were eliminated previously=4 
x Subjects who received additional 
study vaccine since previous visit=1 
x Non-compliance with blood 
sampling schedule at M30=19 
Returned for blood sampling 
(N=166)  
LT-ATP analysis for 
immunogenicity at M54 
(N=148) 
M30 (N=39) 
x Returned but were eliminated 
previously=5 
x Non-compliance with blood 
sampling schedule at M30=33 
x Abnormal increase in antibody 
concentration during the LTFU at 
M30=1 
M42 (N=8) 
x Returned but were eliminated 
previously=6 
x Received vaccine forbidden by 
protocol=1  
x Non-compliance with blood 
sampling schedule=1 
Returned for blood sampling 
(N=79)  
LT-ATP analysis for 
immunogenicity at M54 
(N=76) 
M54 (N=18) 
x Returned but were eliminated 
previously=7 
x Received vaccine forbidden by 
protocol=1  
x Abnormal increase in antibody 
concentration =10 
M66 (N=26) 
x Returned but were eliminated 
previously=17 
x Received vaccine forbidden by 
protocol=1  
x Non-compliance with blood 
sampling schedule at M66=2 
x Abnormal increase in antibody 
concentration during the LTFU at 
M66=6 
Eliminated from LT-ATP 
cohort for immunogenicity
Eliminated from LT-ATP 
cohort for immunogenicity
Year 2 
[M30] 
Year 3 
[M42] 
Year 4 
[M54]
Year 5 
[M66] 
M54 (N=3) 
x Subjects who returned at M54 but 
were eliminated previously=2 
x Abnormal increase in antibody 
concentration=1
M66 (N=6) 
x Subjects who returned at M66 but 
were eliminated previously=4 
x Abnormal increase in antibody 
concentration during the LTFU at 
M66=2 
M42 (N=4) 
x Subjects who returned at M42 but 
were eliminated previously=3 
x Non-compliance with blood 
sampling schedule=1 
Figure 1 CONSORT diagram.
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Figure 2 Percentage of subjects with anti-HBs concentration
≥10 mIU/mL at all long-term follow-up time points (Long-term
ATP cohort for immunogenicity).
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Page 4 of 8As a post-hoc analyses, to ensure that the subjects
participating in the challenge phase of the study were
representative of the initial population that was
enrolled in the primary study, the post-primary
immune response in subjects included in the ATP
cohort for immunogenicity in the challenge phase was
c o m p a r e dt ot h a ti ne x c l u d e ds u b j e c t sa n df o u n dt ob e
comparable irrespective of whether they received the
two-dose or three-dose schedules (overall percentage
of subjects with anti-HBs antibody concentration ≥10
mIU/mL participants: 97.1% [95% CI: 90.1 - 99.7];
non-participants: 97.2% [95% CI: 94.5 - 98.8]; anti-HBs
antibody GMCs: 3037.2 mIU/mL and 3939.8 mIU/mL,
respectively).
Safety and reactogenicity
The challenge dose was generally well-tolerated. Pain at
the site of injection and fatigue were the most frequently
reported solicited local and general symptoms, respec-
tively (33.8% of subjects reported each). None of the
subjects reported local symptoms of Grade 3 intensity,
and one subject (1.3%) reported a general symptom, fati-
gue, of Grade 3 intensity. Five subjects reported unsoli-
cited symptoms that were considered by the investigator
to be vaccine-related. These symptoms were vision
impairment (diagnosed to be transient and due to fati-
gue), injection site paraesthesia, myalgia, allergic derma-
titis and rash (one subject each). One subject reported
Grade 3 unsolicited symptoms, myalgia that was
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Figure 3 Evolution of anti-HBs antibody geometric mean concentrations (GMCs) during the five years follow-up period (Long-term
ATP cohort for immunogenicity) and during the challenge phase (ATP cohort for immunogenicity).
Table 1 Anti-HBs immune response in subjects according to their pre-challenge dose serostatus (ATP cohort for
immunogenicity)
Group Pre-challenge status (mIU/mL) N ≥10 mIU/mL ≥100 mIU/mL GMC
% or Value (95% CI)
HBV_2D <3.3 6 100 (54.1 - 100) 66.7 (22.3 - 95.7) 277.5 (24.7 - 3117.3)
3.3 to <10 6 100 (54.1 - 100) 83.3 (35.9 - 99.6) 821.7 (142.8 - 4729.5)
10 to 100 26 100 (86.8 - 100) 100 (86.8 - 100) 6117.3 (2875.1 - 13015.7)
≥100 15 100 (78.2 - 100) 100 (78.2 - 100) 49745.4 (24663.9 - 100332.9)
HBV_3D <3.3 1 100 (2.5 - 100) 0.0 (0.0 - 97.5) 37.4 (-)
3.3 to <10 0 - - -
10 to 100 9 100 (66.4 - 100) 100 (66.4 - 100) 6048.5 (2414.6 - 15150.9)
≥100 11 100 (71.5 - 100) 100 (71.5 - 100) 65723.7 (34920.1 - 123699.6)
Pooled <3.3 7 100 (59.0 - 100) 57.1 (18.4 - 90.1) 208.4 (26.3 - 1648.7)
3.3 to <10 6 100 (54.1 - 100) 83.3 (35.9 - 99.6) 821.7 (142.8 - 4729.5)
10 to 100 35 100 (90.0 - 100) 100 (90.0 - 100) 6099.5 (3396.3 - 10954.1)
≥100 26 100 (86.8 - 100) 100 (86.8 - 100) 55967.0 (35483.1 - 88276.2)
N = number of subjects with available results; 95% CI = exact 95% confidence interval
GMC = geometric mean concentrations
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these adverse events had resolved by the end of the
study. No SAEs were reported following the challenge
dose.
Discussion
The primary study had established that the immuno-
genicity of a two-dose regimen of the Adult formulation
of hepatitis B vaccine was non-inferior to that of a
three-dose regimen of the Paediatric formulation. Over-
all, both regimens had comparable safety profiles [4]. In
order to address concerns regarding the possibility of
waning immune memory against the hepatitis B antigen
over time, it was essential to evaluate the duration of
persistent immunity following the two-dose hepatitis B
primary immunisation.
Studies assessing the immunogenicity of two- and
three-dose primary vaccination against hepatitis B in
adolescents have reported seroprotection rates between
93.4% and 99.5% and anti-HBs antibody GMCs up to
4155 mIU/mL [12,13,15]. Data on the long-term persis-
tence of anti-HBs antibodies in adolescents following a
three-dose schedule as obtained from two published
long-term follow-up studies had established that 94.1%
of adolescents retained anti-HBs antibody concentra-
tions ≥10 mIU/mL for at least five years, while 91.2% of
adolescents retained anti-HBs antibody concentrations
≥10 mIU/mL up to 10 years after completion of the pri-
mary vaccination schedule [13,16]. The findings from
the present study are in line with these previous long-
term follow-up studies. In this study, the anti-HBs anti-
bodies persisted for at least five years after primary vac-
cination, irrespective of whether the subjects received
the two- or three-dose schedules. At the end of the
long-term follow-up period, 79.5% and 91.4% subjects in
the HBV_2D and HBV_3D groups, respectively showed
anti-HBs antibody concentrations ≥10 mIU/mL.
The anti-HBs antibody GMC evolution observed in
the present study is similar to observations from pre-
vious studies [2,11], where the GMCs declined rapidly
in the first year after primary vaccination, followed by a
more gradual decrease over the subsequent years. The
anti-HBs antibody GMC observed in the HBV_3D
group was comparatively higher than that observed in
t h eH B V _ 2 Dg r o u p ,a ta l lf o l l o w - u pt i m ep o i n t s .H o w -
ever, the evolution of anti-HBs antibody GMC observed
throughout the follow-up period was similar in both
groups. Of note, the fold increase in anti-HBs antibody
GMC following the challenge dose was slightly higher in
the HBV_2D group than in the HBV_3D group (108-
fold and 95-fold, respectively). Thus, it is evident that
the subjects in both groups, irrespective of their anti-
HBs antibody levels prior to the challenge dose had suf-
ficient immune memory to mount an effective
anamnestic response to the challenge dose administered
five years after completion of the primary vaccination
course.
These results are consistent with previous long-term
studies with two- and three-dose schedules of the hepa-
titis B study vaccine which have reported that five to
ten years after primary vaccination, between 81.0% and
99% of children and adults had anti-HBs antibody con-
centrations ≥10 mIU/mL [17-19]. In addition, the fact
that all subjects in the present study could mount an
anamnestic response to the challenge dose indicates
strong immune memory against the hepatitis B vaccine
antigen.
A potential weakness of this study is that the sample
size calculation was based on the objective of the pri-
mary study (to compare the immune response induced
by the Adult and Paediatric formulations of the hepatitis
B study vaccine following a two-dose or three-dose pri-
mary vaccination course) and hence did not account for
the attrition of subjects over a period of five years. How-
ever, the population at the start of the study and the
population followed up were comparable in terms of
anti-HBs response to primary vaccination and demo-
graphic characteristics, as evident from the post-hoc
analysis. Therefore there was no bias in the selection of
the final study cohort.
The observations from this study are in line with pre-
vious reports that the decrease in anti-HBs antibody
concentrations to even undetectable levels does not
necessarily indicate loss of protection in the long-term
and that immunological memory can outlast the loss of
antibodies [1,20]. The data from two separate studies in
infants and adolescents that evaluated persistence of
anti-HBs antibodies five and ten years after primary vac-
cination have further established these observations
[13,21]. The fact that the vaccinees with undetectable
levels of anti-HBs antibodies or waning antibody levels
responded with an anamnestic response to the challenge
dose indicate that there is currently no evidence that
booster dose of hepatitis B vaccine is required after a
successful primary vaccination [13,21].
A two-dose schedule of GSK Biologicals’ Engerix-B™
Adult (anti-HBsAg content: 20 μg), which has a good
safety and immunogenicity profile and is generally well-
tolerated, is therefore a suitable alternative to the stan-
dard three-dose schedule of the Paediatric formulation
(for adolescents aged 11+) and may facilitate higher
immunisation completion rates [21-24] with the reduc-
tion in the required number of injections and clinical
visits. In addition, a catch-up regimen of a two-dose
schedule in older adolescents susceptible to the disease
and in whom compliance with a three-dose Paediatric
dosing schedule is in doubt, may also be used in order
to improve population-based immunity [21].
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The two-dose schedule of the Adult formulation of
hepatitis B vaccine when administered to adolescents
induced persistence of detectable anti-HBs antibodies
for at least five years after completion of the primary
vaccination schedule. The strong anamnestic response
following the challenge dose regardless of the priming
schedules provides the evidence of strong immunologi-
cal memory for at least five years following vaccination.
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